KR102363621B1 - 매크롤라이드 그리고 그의 제조방법 및 용도 - Google Patents

매크롤라이드 그리고 그의 제조방법 및 용도 Download PDF

Info

Publication number
KR102363621B1
KR102363621B1 KR1020157031656A KR20157031656A KR102363621B1 KR 102363621 B1 KR102363621 B1 KR 102363621B1 KR 1020157031656 A KR1020157031656 A KR 1020157031656A KR 20157031656 A KR20157031656 A KR 20157031656A KR 102363621 B1 KR102363621 B1 KR 102363621B1
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
certain embodiments
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157031656A
Other languages
English (en)
Korean (ko)
Other versions
KR20150140735A (ko
Inventor
앤드류 지. 마이어스
이안 바스 세이플
지양 장
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority to KR1020227004693A priority Critical patent/KR102528984B1/ko
Publication of KR20150140735A publication Critical patent/KR20150140735A/ko
Application granted granted Critical
Publication of KR102363621B1 publication Critical patent/KR102363621B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157031656A 2013-04-04 2014-04-04 매크롤라이드 그리고 그의 제조방법 및 용도 Active KR102363621B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227004693A KR102528984B1 (ko) 2013-04-04 2014-04-04 매크롤라이드 그리고 그의 제조방법 및 용도

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361808441P 2013-04-04 2013-04-04
US61/808,441 2013-04-04
US201361832639P 2013-06-07 2013-06-07
US61/832,639 2013-06-07
US201461946604P 2014-02-28 2014-02-28
US61/946,604 2014-02-28
PCT/US2014/033025 WO2014165792A2 (en) 2013-04-04 2014-04-04 Macrolides and methods of their preparation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227004693A Division KR102528984B1 (ko) 2013-04-04 2014-04-04 매크롤라이드 그리고 그의 제조방법 및 용도

Publications (2)

Publication Number Publication Date
KR20150140735A KR20150140735A (ko) 2015-12-16
KR102363621B1 true KR102363621B1 (ko) 2022-02-25

Family

ID=51659360

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157031656A Active KR102363621B1 (ko) 2013-04-04 2014-04-04 매크롤라이드 그리고 그의 제조방법 및 용도
KR1020227004693A Active KR102528984B1 (ko) 2013-04-04 2014-04-04 매크롤라이드 그리고 그의 제조방법 및 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227004693A Active KR102528984B1 (ko) 2013-04-04 2014-04-04 매크롤라이드 그리고 그의 제조방법 및 용도

Country Status (11)

Country Link
US (3) US9982005B2 (enExample)
EP (2) EP2988597B1 (enExample)
JP (3) JP6437523B2 (enExample)
KR (2) KR102363621B1 (enExample)
CN (2) CN105246334A (enExample)
AU (3) AU2014248014B2 (enExample)
BR (1) BR112015025159A2 (enExample)
CA (2) CA3130061C (enExample)
IL (1) IL241878B (enExample)
MX (2) MX377459B (enExample)
WO (1) WO2014165792A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
IN2014DN08939A (enExample) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2016057798A1 (en) * 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
AU2016230027A1 (en) * 2015-03-06 2017-09-28 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
WO2016154591A1 (en) * 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
HK1250719A1 (zh) * 2015-03-25 2019-01-11 President And Fellows Of Harvard College 脱氧糖胺的合成
GB201608236D0 (en) * 2016-05-11 2016-06-22 Fidelta D O O Seco macrolide compounds
CA3091413A1 (en) * 2017-02-17 2018-08-23 Cempra Pharmaceuticals, Inc. Triazole-containing macrolides and ophthalmic uses therefor
WO2018201076A2 (en) 2017-04-28 2018-11-01 Macrolide Pharmaceuticals Inc. Macrolides with modified desosamine sugars and uses thereof
KR20210133950A (ko) 2018-11-19 2021-11-08 지카니 테라퓨틱스, 인크. C10-알킬렌 치환된 13-원 매크롤라이드 및 이의 용도
BR112021009607A2 (pt) * 2018-11-19 2021-08-10 Zikani Therapeutics, Inc. macrolídeos de 13 membros substituídos c10-cíclicos e usos dos mesmos
CN114591286B (zh) * 2021-04-12 2023-05-23 南京大学 新型大环内酯化合物acautalides A-C及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060096158A1 (en) * 2004-11-08 2006-05-11 Robinson J M Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same
US20080021226A1 (en) * 2005-10-13 2008-01-24 Eisai R&D Management Co., Ltd. Process for total synthesis of pladienolide B and pladienolide D

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
ZA859575B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Oxetanones
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
FR2692579B1 (fr) * 1992-06-19 1995-06-02 Roussel Uclaf Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
AU6082594A (en) 1993-01-11 1994-08-15 Merck & Co., Inc. 8a-aza and 9a-aza macrolide antibiotics, and a process for producing same and methods of use
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
JP3652394B2 (ja) * 1995-01-27 2005-05-25 高砂香料工業株式会社 Ｎ−置換−７−アミノ−５−ヒドロキシ−３−オキソヘプタン酸誘導体およびその製造法
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
HN1998000074A (es) * 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
WO1999000125A1 (en) * 1997-06-27 1999-01-07 Merck & Co., Inc. 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9814006D0 (en) 1998-06-29 1998-08-26 Biotica Tech Ltd Polyketides and their synthesis
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US6262030B1 (en) * 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
CN1373767A (zh) 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
US6590083B1 (en) * 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials
HRP990116B1 (en) 1999-04-20 2007-10-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. NOVEL 8a AND 9a- 15-MEMBERED LACTAMES
HK1045523A1 (zh) 1999-05-24 2002-11-29 辉瑞产品公司 13-甲基红霉素衍生物
AU6316400A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
BR0009101A (pt) 1999-08-24 2002-02-05 Abbott Lab 9a-azalidas com atividade antibacteriana
AU779748C (en) 2000-01-27 2005-12-08 Zoetis Services Llc Azalide antibiotic compositions
JP4596591B2 (ja) * 2000-03-09 2010-12-08 塩野義製薬株式会社 ８ａ−オキサホモエリスロマイシン誘導体、製造方法、合成中間体および医薬組成物
US6440942B1 (en) 2000-12-22 2002-08-27 Enanta Pharmaceuticals, Inc. 14-membered macrolides derived from leucomycins
NZ533282A (en) 2001-12-05 2006-09-29 Ortho Mcneil Pharm Inc 6-O-Acyl ketolide derivatives of erythromycine useful as antibacterials
US8063021B2 (en) 2002-01-17 2011-11-22 Kosan Biosciences Incorporated Ketolide anti-infective compounds
BR0316746A (pt) 2002-11-29 2005-10-18 Mercian Corp Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)
WO2004065346A1 (ja) 2003-01-21 2004-08-05 Sumitomo Chemical Company, Limited （－）－テトラヒドロリプスタチンおよびその中間体の製造方法
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
CN1530079A (zh) 2003-03-13 2004-09-22 钱本文 中空分叉髓内钉
HRP20030381B1 (en) 2003-05-14 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 3-DECLADINOZYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERYTHROMICYNE A
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
US7767797B1 (en) 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
WO2006046112A2 (en) 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
EP1841775A2 (en) 2005-01-12 2007-10-10 Alpharma APS Erythromycin derivatives as antibacterial agents
CN101103039A (zh) * 2005-01-12 2008-01-09 阿尔法马股份公司 作为抗菌剂的红霉素衍生物
CN101142225B (zh) 2005-01-13 2011-09-07 葛兰素集团有限公司 具有抗炎活性的大环内酯
EP1879903A1 (en) 2005-05-10 2008-01-23 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Ether linked macrolides useful for the treatment of microbial infections
RU2008106915A (ru) 2005-07-26 2009-09-10 Меркле Гмбх (De) Макролидные конъюгаты пирролиновых и индолизиновых соединений
WO2007034909A1 (ja) * 2005-09-22 2007-03-29 Kaneka Corporation （３ｒ，５ｒ）－７－アミノ－３，５－ジヒドロキシヘプタン酸誘導体の製造法
US8097708B2 (en) 2006-02-07 2012-01-17 Taisho Pharmaceutical Co., Ltd. 10a-Azalide compound
JP4468487B1 (ja) 2007-03-13 2010-05-26 ファイザー・プロダクツ・インク エリスロマイシンをベースとするマクロライド
DE102007046388A1 (de) * 2007-09-21 2009-09-10 Universität Hamburg Entwicklung eines Bindungsassays und Darstellung neuartiger Inhibitoren des Myelin Assoziierten Glycoproteins
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20090209547A1 (en) * 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
KR100980379B1 (ko) * 2008-04-02 2010-09-06 주식회사 파마코스텍 광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법
WO2010015703A2 (en) 2008-08-07 2010-02-11 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Novel 6-o-substituted 15-membered 8a- and 9a-lactams
HRP20160222T1 (hr) 2008-10-24 2016-04-08 Cempra Pharmaceuticals, Inc. Biozaštite uporabom makrolida koji sadrže triazol
US8865662B2 (en) 2009-08-13 2014-10-21 Basilea Pharmaceutica Ag Macrolides and their use
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
JP5711352B2 (ja) 2010-03-22 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用
WO2011131749A1 (en) 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
WO2012001089A1 (en) 2010-07-01 2012-01-05 Novartis Ag Antibiotic compositions
WO2012016186A1 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
US8796474B1 (en) 2010-08-23 2014-08-05 Rutgers, The State University Of New Jersey Macrolide compounds and methods and intermediates useful for their preparation
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012051126A2 (en) * 2010-10-10 2012-04-19 Synovo Gmbh Anti-inflammatory macrolides
DK2640728T3 (en) * 2010-11-16 2016-11-28 Merial Inc NEW MONENSINDERIVATER FOR TREATMENT AND PREVENTION OF protozoal INFECTIONS
CN102690297A (zh) 2011-03-22 2012-09-26 连云港海康生物科技有限公司 一种壳寡糖季铵盐及其合成方法
CN103619863B (zh) 2011-03-22 2016-03-16 沃克哈特有限公司 酮内酯化合物的制备方法
JP6023192B2 (ja) 2011-07-01 2016-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状インスリン分解酵素（ｉｄｅ）阻害剤およびその使用
IN2014DN08939A (enExample) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
EP2968384A4 (en) 2013-03-15 2017-02-15 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
WO2016057798A1 (en) 2014-10-08 2016-04-14 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
HK1250719A1 (zh) 2015-03-25 2019-01-11 President And Fellows Of Harvard College 脱氧糖胺的合成

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060096158A1 (en) * 2004-11-08 2006-05-11 Robinson J M Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same
US20080021226A1 (en) * 2005-10-13 2008-01-24 Eisai R&D Management Co., Ltd. Process for total synthesis of pladienolide B and pladienolide D

Also Published As

Publication number Publication date
US20180298048A1 (en) 2018-10-18
US20160052951A1 (en) 2016-02-25
EP2988597A4 (en) 2017-03-08
US10913764B2 (en) 2021-02-09
KR20150140735A (ko) 2015-12-16
AU2014248014A1 (en) 2015-10-22
JP6437523B2 (ja) 2018-12-12
US9982005B2 (en) 2018-05-29
WO2014165792A3 (en) 2014-12-24
BR112015025159A2 (pt) 2017-07-18
JP6850783B2 (ja) 2021-03-31
MX2020011518A (es) 2022-10-17
JP7111381B2 (ja) 2022-08-02
MX2015014026A (es) 2016-08-03
KR102528984B1 (ko) 2023-05-08
CN105246334A (zh) 2016-01-13
CA2908575A1 (en) 2014-10-09
CN111825733A (zh) 2020-10-27
JP2019055968A (ja) 2019-04-11
US20220332747A1 (en) 2022-10-20
AU2020281043A1 (en) 2021-01-07
WO2014165792A2 (en) 2014-10-09
US11634449B2 (en) 2023-04-25
CA3130061C (en) 2024-05-28
AU2019200494B2 (en) 2020-09-17
AU2020281043B9 (en) 2023-02-09
AU2019200494A1 (en) 2019-02-14
AU2020281043C1 (en) 2023-06-01
CA3130061A1 (en) 2014-10-09
EP4095146A1 (en) 2022-11-30
AU2020281043B2 (en) 2023-02-02
JP2020169174A (ja) 2020-10-15
JP2016520551A (ja) 2016-07-14
IL241878B (en) 2021-09-30
EP2988597A2 (en) 2016-03-02
CA2908575C (en) 2021-11-16
KR20220025901A (ko) 2022-03-03
MX377459B (es) 2025-03-10
AU2014248014B2 (en) 2018-11-08
EP2988597B1 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
KR102363621B1 (ko) 매크롤라이드 그리고 그의 제조방법 및 용도
US20230109357A1 (en) 14-membered ketolides and methods of their preparation and use
HK40085225A (en) Macrolides and methods of their preparation and use
HK1225228B (en) Macrolides and methods of their preparation and use
HK1225228A1 (en) Macrolides and methods of their preparation and use
CN119403559A (zh) 林可酰胺及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151104

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190404

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201229

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201229

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210331

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190404

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20211110

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20211019

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210720

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210331

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190404

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220211

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220211

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250122

Start annual number: 4

End annual number: 4